Zamal Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Zamal Ahmed has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
- John A. Tainer
10Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
15 shared publications Davide Moiani
6 shared publications- Dihua Yu
Department of Molecular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
6 shared publications Yuan Zhang
Departments of Molecular and Cellular Oncology and Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, USA
6 shared publicationsAkosua Badu-Nkansah
5 shared publications- Arseniy E. Yuzhalin
Sirius University of Science and Technologies
5 shared publications
Latest Publications
- 29 October 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (18) , 2278-2293
A dual MYC and GSPT1 protein degrader for MYC-driven hematologic malignancies
Direct targeting of the oncoprotein MYC has not yet been successful. Here we report a novel dual protein degrader, GT19630, which binds directly to MYC and G1 to S phase transition protein 1 (GSPT1). GT19630 disrupts a novel feedforward loop of MYC and GSPT1, in which MYC promotes transcription of GSPT1, and GSPT1 senses the stop codon of MYC to properly terminate its translation. The agent induces an integrated stress response and abrogates oxidative phosphorylation through inhibition of the tricarboxylic acid cycle, resulting in apoptosis. GT19630 has superior activity compared with GSPT1-targeting molecular glues. GT19630 induces profound antiproliferative effects and apoptosis at low nanomolar concentrations in a multitude of leukemia and lymphoma cell lines and primary samples, including those with TP53 mutations. GT19630 is highly active in vivo in models of therapy-resistant hematologic malignancies, including Burkitt lymphoma, acute myeloid leukemia (AML), and multiple myeloma. CD34+ AML blasts overexpress MYC protein compared with normal hematopoietic stem/progenitor cells (HSPCs), and GT19630 induces greater cytotoxicity in AML cells compared with normal HSPCs. Further, GT19630 restores sensitivity to venetoclax and profoundly prolongs survival in vivo in venetoclax-resistant AML. GT19630 was well tolerated in humanized Crbn mice. In conclusion, our data support the development of the MYC/GSPT1 degrader GT19630 as a therapeutic strategy for MYC-driven hematologic malignancies.
- 29 October 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (18) , 2278-2293
A dual MYC and GSPT1 protein degrader for MYC-driven hematologic malignancies
Direct targeting of the oncoprotein MYC has not yet been successful. Here we report a novel dual protein degrader, GT19630, which binds directly to MYC and G1 to S phase transition protein 1 (GSPT1). GT19630 disrupts a novel feedforward loop of MYC and GSPT1, in which MYC promotes transcription of GSPT1, and GSPT1 senses the stop codon of MYC to properly terminate its translation. The agent induces an integrated stress response and abrogates oxidative phosphorylation through inhibition of the tricarboxylic acid cycle, resulting in apoptosis. GT19630 has superior activity compared with GSPT1-targeting molecular glues. GT19630 induces profound antiproliferative effects and apoptosis at low nanomolar concentrations in a multitude of leukemia and lymphoma cell lines and primary samples, including those with TP53 mutations. GT19630 is highly active in vivo in models of therapy-resistant hematologic malignancies, including Burkitt lymphoma, acute myeloid leukemia (AML), and multiple myeloma. CD34+ AML blasts overexpress MYC protein compared with normal hematopoietic stem/progenitor cells (HSPCs), and GT19630 induces greater cytotoxicity in AML cells compared with normal HSPCs. Further, GT19630 restores sensitivity to venetoclax and profoundly prolongs survival in vivo in venetoclax-resistant AML. GT19630 was well tolerated in humanized Crbn mice. In conclusion, our data support the development of the MYC/GSPT1 degrader GT19630 as a therapeutic strategy for MYC-driven hematologic malignancies.
- Open Access
- 17 September 2026
- Published by Springer Nature in Communications Chemistry
Structural basis for substrate-assisted catalysis and small-molecule inhibition of alphavirus macrodomains
Sporadic alphavirus infections are pandemic threats that evade innate immunity via macrodomains which remove host mono-ADP-ribose (ADPr). Through high-resolution crystallography of apo and ADPr-bound forms, we here define a conserved MacroD-like fold and a shared hydrogen-bonding network for macrodomains from Eastern equine encephalitis (EEEV), Venezuelan equine encephalitis (VEEV), and Chikungunya (CHIKV) alphaviruses. Our detailed active site structures support a substrate-assisted hydrolysis mechanism where the ADPr α-phosphate activates the catalytic water for nucleophilic attack. Furthermore, we identify the suramin trisulfonic moiety as a potent inhibitor. Crystal structures with solution-state SAXS show suramin occupies the ADPr-binding pocket and induces reversible, inhibitor-mediated oligomerization. Biophysical and enzymatic assays confirm low-micromolar inhibition of EEEV glycohydrolase activity, while cell-based trans -replication assays demonstrate broad-spectrum suppression of EEEV, VEEV, and CHIKV replication. Collectively, our findings define the structural basis for alphaviral macrodomain catalysis, key alphaviral macrodomain druggable features, and a promising scaffold for targeted broad-spectrum antiviral therapeutics.
- 17 September 2026
- Published by Springer Nature in Communications Chemistry
Open AccessStructural basis for substrate-assisted catalysis and small-molecule inhibition of alphavirus macrodomains
Sporadic alphavirus infections are pandemic threats that evade innate immunity via macrodomains which remove host mono-ADP-ribose (ADPr). Through high-resolution crystallography of apo and ADPr-bound forms, we here define a conserved MacroD-like fold and a shared hydrogen-bonding network for macrodomains from Eastern equine encephalitis (EEEV), Venezuelan equine encephalitis (VEEV), and Chikungunya (CHIKV) alphaviruses. Our detailed active site structures support a substrate-assisted hydrolysis mechanism where the ADPr α-phosphate activates the catalytic water for nucleophilic attack. Furthermore, we identify the suramin trisulfonic moiety as a potent inhibitor. Crystal structures with solution-state SAXS show suramin occupies the ADPr-binding pocket and induces reversible, inhibitor-mediated oligomerization. Biophysical and enzymatic assays confirm low-micromolar inhibition of EEEV glycohydrolase activity, while cell-based trans -replication assays demonstrate broad-spectrum suppression of EEEV, VEEV, and CHIKV replication. Collectively, our findings define the structural basis for alphaviral macrodomain catalysis, key alphaviral macrodomain druggable features, and a promising scaffold for targeted broad-spectrum antiviral therapeutics.
- Open Access
Characteristics and Clinical Outcomes of BRCA Germline Mutation Carriers with Advanced Breast Cancer Treated with PARP (Poly ADP-Ribose Polymerase) Inhibitors: A Single-Institution Experience
Background/Objectives: Several trials have highlighted the importance of PARP inhibitors (PARPi) in the treatment of BRCA-associated breast cancers (BC), initiating changes in practice. However, data on the real-life outcomes of PARPi therapy is limited. In this study, we characterized the clinical characteristics and outcomes of patients with advanced BC and germline BRCA pathogenic variants (PVs) who received PARPi therapy. Methods: We conducted a retrospective single-institution cohort study of patients with advanced BC and germline BRCA1/2 PVs treated with PARPi. Outcomes included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Survival was estimated using Kaplan–Meier methods, and prognostic factors were evaluated using Cox regression analysis. Results: Of the 107 patients treated with PARPi, 48 (44.9%) and 59 (55.1%) had BRCA1 and BRCA2 PVs, respectively. Ninety-seven patients (90.7%) had invasive ductal carcinoma and 42 (39.3%) had triple-negative BC. Nineteen (17.8%) patients had de novo metastatic BC. Sixty-two (57.9%) patients received at least one line of systemic therapy before PARPi; 24 (22.4%) patients received prior platinum. ORR was 62.6%, and the median duration of response (DoR) was 7 months (range, 2.1–96.2). The median PFS was 9 months (95% CI, 6.9–10.5) and median OS was 25.8 months (95% CI, 18.7–31.5). In multivariable models for PFS, bone metastases (HR = 2.25; 95% CI, 1.40–3.61; p = 0.0008) and lung metastases (HR = 2.40; 95% CI, 1.45–3.98; p = 0.0007) were independently associated with increased risk of progression or death. In multivariable models for OS, brain metastases (HR = 3.54; 95% CI, 1.59–7.90; p = 0.0020), bone metastases (HR = 2.22; 95% CI, 1.27–3.88; p = 0.0050), and lung metastases (HR = 2.38; 95% CI, 1.38–4.11; p = 0.0018), were independently associated with increased risk of death. Conclusions: The clinical outcomes of our real-world patients are similar to those reported in previous clinical trials. In addition, metastatic site distribution was independently prognostic for survival outcomes and may support baseline risk stratification at the time of PARPi initiation. Further studies of predictive markers of response and resistance, as well as sequencing with platinums and combinations with other targeted agents, are needed to optimize the benefits of PARPi in this patient population.
Open AccessCharacteristics and Clinical Outcomes of BRCA Germline Mutation Carriers with Advanced Breast Cancer Treated with PARP (Poly ADP-Ribose Polymerase) Inhibitors: A Single-Institution Experience
Background/Objectives: Several trials have highlighted the importance of PARP inhibitors (PARPi) in the treatment of BRCA-associated breast cancers (BC), initiating changes in practice. However, data on the real-life outcomes of PARPi therapy is limited. In this study, we characterized the clinical characteristics and outcomes of patients with advanced BC and germline BRCA pathogenic variants (PVs) who received PARPi therapy. Methods: We conducted a retrospective single-institution cohort study of patients with advanced BC and germline BRCA1/2 PVs treated with PARPi. Outcomes included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Survival was estimated using Kaplan–Meier methods, and prognostic factors were evaluated using Cox regression analysis. Results: Of the 107 patients treated with PARPi, 48 (44.9%) and 59 (55.1%) had BRCA1 and BRCA2 PVs, respectively. Ninety-seven patients (90.7%) had invasive ductal carcinoma and 42 (39.3%) had triple-negative BC. Nineteen (17.8%) patients had de novo metastatic BC. Sixty-two (57.9%) patients received at least one line of systemic therapy before PARPi; 24 (22.4%) patients received prior platinum. ORR was 62.6%, and the median duration of response (DoR) was 7 months (range, 2.1–96.2). The median PFS was 9 months (95% CI, 6.9–10.5) and median OS was 25.8 months (95% CI, 18.7–31.5). In multivariable models for PFS, bone metastases (HR = 2.25; 95% CI, 1.40–3.61; p = 0.0008) and lung metastases (HR = 2.40; 95% CI, 1.45–3.98; p = 0.0007) were independently associated with increased risk of progression or death. In multivariable models for OS, brain metastases (HR = 3.54; 95% CI, 1.59–7.90; p = 0.0020), bone metastases (HR = 2.22; 95% CI, 1.27–3.88; p = 0.0050), and lung metastases (HR = 2.38; 95% CI, 1.38–4.11; p = 0.0018), were independently associated with increased risk of death. Conclusions: The clinical outcomes of our real-world patients are similar to those reported in previous clinical trials. In addition, metastatic site distribution was independently prognostic for survival outcomes and may support baseline risk stratification at the time of PARPi initiation. Further studies of predictive markers of response and resistance, as well as sequencing with platinums and combinations with other targeted agents, are needed to optimize the benefits of PARPi in this patient population.
- Open Access
- 29 January 2026
- Published by Springer Nature in Research Square
Structural basis for substrate-assisted catalysis and small-molecule inhibition of alphavirus macrodomains
Sporadic alphavirus infections are pandemic threats that evade innate immunity via macrodomains which remove host mono-ADP-ribose (ADPr). Through high-resolution crystallography of apo and ADPr-bound forms, we here define a conserved MacroD-like fold and a shared hydrogen-bonding network for macrodomains from Eastern equine encephalitis (EEEV), Venezuelan equine encephalitis (VEEV), and Chikungunya (CHIKV) alphaviruses. Our detailed active site structures support a substrate-assisted hydrolysis mechanism where the ADPr α-phosphate activates the catalytic water for nucleophilic attack. Furthermore, we identify the suramin trisulfonic moiety as a potent inhibitor. Crystal structures with solution-state SAXS show suramin occupies the ADPr-binding pocket and induces reversible, inhibitor-mediated oligomerization. Biophysical and enzymatic assays confirm low-micromolar inhibition of EEEV glycohydrolase activity, while cell-based trans-replication assays demonstrate broad-spectrum suppression of EEEV, VEEV, and CHIKV replication. Collectively, our findings define the structural basis for alphaviral macrodomain catalysis, key alphaviral macrodomain druggable features, and a promising scaffold for targeted broad-spectrum antiviral therapeutics.
- 29 January 2026
- Published by Springer Nature in Research Square
Open AccessStructural basis for substrate-assisted catalysis and small-molecule inhibition of alphavirus macrodomains
Sporadic alphavirus infections are pandemic threats that evade innate immunity via macrodomains which remove host mono-ADP-ribose (ADPr). Through high-resolution crystallography of apo and ADPr-bound forms, we here define a conserved MacroD-like fold and a shared hydrogen-bonding network for macrodomains from Eastern equine encephalitis (EEEV), Venezuelan equine encephalitis (VEEV), and Chikungunya (CHIKV) alphaviruses. Our detailed active site structures support a substrate-assisted hydrolysis mechanism where the ADPr α-phosphate activates the catalytic water for nucleophilic attack. Furthermore, we identify the suramin trisulfonic moiety as a potent inhibitor. Crystal structures with solution-state SAXS show suramin occupies the ADPr-binding pocket and induces reversible, inhibitor-mediated oligomerization. Biophysical and enzymatic assays confirm low-micromolar inhibition of EEEV glycohydrolase activity, while cell-based trans-replication assays demonstrate broad-spectrum suppression of EEEV, VEEV, and CHIKV replication. Collectively, our findings define the structural basis for alphaviral macrodomain catalysis, key alphaviral macrodomain druggable features, and a promising scaffold for targeted broad-spectrum antiviral therapeutics.
- Open Access
- 8 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
GRB2 stabilizes RAD51 at reversed replication forks suppressing genomic instability and innate immunity against cancer
Growth factor receptor-bound protein 2 (GRB2) is a cytoplasmic adapter for tyrosine kinase signaling and a nuclear adapter for homology-directed-DNA repair. Here we find nuclear GRB2 protects DNA at stalled replication forks from MRE11-mediated degradation in the BRCA2 replication fork protection axis. Mechanistically, GRB2 binds and inhibits RAD51 ATPase activity to stabilize RAD51 on stalled replication forks. In GRB2-depleted cells, PARP inhibitor (PARPi) treatment releases DNA fragments from stalled forks into the cytoplasm that activate the cGAS–STING pathway to trigger pro-inflammatory cytokine production. Moreover in a syngeneic mouse metastatic ovarian cancer model, GRB2 depletion in the context of PARPi treatment reduced tumor burden and enabled high survival consistent with immune suppression of cancer growth. Collective findings unveil GRB2 function and mechanism for fork protection in the BRCA2-RAD51-MRE11 axis and suggest GRB2 as a potential therapeutic target and an enabling predictive biomarker for patient selection for PARPi and immunotherapy combination.
- 8 March 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Open AccessGRB2 stabilizes RAD51 at reversed replication forks suppressing genomic instability and innate immunity against cancer
Growth factor receptor-bound protein 2 (GRB2) is a cytoplasmic adapter for tyrosine kinase signaling and a nuclear adapter for homology-directed-DNA repair. Here we find nuclear GRB2 protects DNA at stalled replication forks from MRE11-mediated degradation in the BRCA2 replication fork protection axis. Mechanistically, GRB2 binds and inhibits RAD51 ATPase activity to stabilize RAD51 on stalled replication forks. In GRB2-depleted cells, PARP inhibitor (PARPi) treatment releases DNA fragments from stalled forks into the cytoplasm that activate the cGAS–STING pathway to trigger pro-inflammatory cytokine production. Moreover in a syngeneic mouse metastatic ovarian cancer model, GRB2 depletion in the context of PARPi treatment reduced tumor burden and enabled high survival consistent with immune suppression of cancer growth. Collective findings unveil GRB2 function and mechanism for fork protection in the BRCA2-RAD51-MRE11 axis and suggest GRB2 as a potential therapeutic target and an enabling predictive biomarker for patient selection for PARPi and immunotherapy combination.
- Open Access
- 14 July 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1-14
The combined action of the intracellular regions regulates FGFR2 kinase activity
Receptor tyrosine kinases (RTKs) are typically activated through a precise sequence of intracellular phosphorylation events starting with a tyrosine residue on the activation loop (A-loop) of the kinase domain (KD). From this point the mono-phosphorylated enzyme is active, but subject to stringent regulatory mechanisms which can vary dramatically across the different RTKs. In the absence of extracellular stimulation, fibroblast growth factor receptor 2 (FGFR2) exists in the mono-phosphorylated state in which catalytic activity is regulated to allow rapid response upon ligand binding, whilst restricting ligand-independent activation. Failure of this regulation is responsible for pathologic outcomes including cancer. Here we reveal the molecular mechanistic detail of KD control based on combinatorial interactions of the juxtamembrane (JM) and the C-terminal tail (CT) regions of the receptor. JM stabilizes the asymmetric dimeric KD required for substrate phosphorylation, whilst CT binding opposes dimerization, and down-regulates activity. Direct binding between JM and CT delays the recruitment of downstream effector proteins adding a further control step as the receptor proceeds to full activation. Our findings underscore the diversity in mechanisms of RTK oligomerisation and activation.
- 14 July 2023
- Published by Springer Nature in Communications Biology
- Vol. 6 (1) , 1-14
Open AccessThe combined action of the intracellular regions regulates FGFR2 kinase activity
Receptor tyrosine kinases (RTKs) are typically activated through a precise sequence of intracellular phosphorylation events starting with a tyrosine residue on the activation loop (A-loop) of the kinase domain (KD). From this point the mono-phosphorylated enzyme is active, but subject to stringent regulatory mechanisms which can vary dramatically across the different RTKs. In the absence of extracellular stimulation, fibroblast growth factor receptor 2 (FGFR2) exists in the mono-phosphorylated state in which catalytic activity is regulated to allow rapid response upon ligand binding, whilst restricting ligand-independent activation. Failure of this regulation is responsible for pathologic outcomes including cancer. Here we reveal the molecular mechanistic detail of KD control based on combinatorial interactions of the juxtamembrane (JM) and the C-terminal tail (CT) regions of the receptor. JM stabilizes the asymmetric dimeric KD required for substrate phosphorylation, whilst CT binding opposes dimerization, and down-regulates activity. Direct binding between JM and CT delays the recruitment of downstream effector proteins adding a further control step as the receptor proceeds to full activation. Our findings underscore the diversity in mechanisms of RTK oligomerisation and activation.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1
Supplementary Data from Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1
Supplementary Data from Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1
Supplementary Data from Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1
Supplementary Data from Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1
Despite the popular use of dietary supplements during conventional cancer treatments, their impacts on the efficacies of prevalent immunotherapies, including immune-checkpoint therapy (ICT), are unknown. Surprisingly, our analyses of electronic health records revealed that ICT-treated patients with cancer who took vitamin E (VitE) had significantly improved survival. In mouse models, VitE increased ICT antitumor efficacy, which depended on dendritic cells (DC). VitE entered DCs via the SCARB1 receptor and restored tumor-associated DC functionality by directly binding to and inhibiting protein tyrosine phosphatase SHP1, a DC-intrinsic checkpoint. SHP1 inhibition, genetically or by VitE treatment, enhanced tumor antigen cross-presentation by DCs and DC-derived extracellular vesicles (DC-EV), triggering systemic antigen-specific T-cell antitumor immunity. Combining VitE with DC-recruiting cancer vaccines or immunogenic chemotherapies greatly boosted ICT efficacy in animals. Therefore, combining VitE supplement or SHP1-inhibited DCs/DC-EVs with DC-enrichment therapies could substantially augment T-cell antitumor immunity and enhance the efficacy of cancer immunotherapies.Significance:The impacts of nutritional supplements on responses to immunotherapies remain unexplored. Our study revealed that dietary vitamin E binds to and inhibits DC checkpoint SHP1 to increase antigen presentation, prime antitumor T-cell immunity, and enhance immunotherapy efficacy. VitE-treated or SHP1-silenced DCs/DC-EVs could be developed as potent immunotherapies.This article is highlighted in the In This Issue feature, p. 1599
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1
Despite the popular use of dietary supplements during conventional cancer treatments, their impacts on the efficacies of prevalent immunotherapies, including immune-checkpoint therapy (ICT), are unknown. Surprisingly, our analyses of electronic health records revealed that ICT-treated patients with cancer who took vitamin E (VitE) had significantly improved survival. In mouse models, VitE increased ICT antitumor efficacy, which depended on dendritic cells (DC). VitE entered DCs via the SCARB1 receptor and restored tumor-associated DC functionality by directly binding to and inhibiting protein tyrosine phosphatase SHP1, a DC-intrinsic checkpoint. SHP1 inhibition, genetically or by VitE treatment, enhanced tumor antigen cross-presentation by DCs and DC-derived extracellular vesicles (DC-EV), triggering systemic antigen-specific T-cell antitumor immunity. Combining VitE with DC-recruiting cancer vaccines or immunogenic chemotherapies greatly boosted ICT efficacy in animals. Therefore, combining VitE supplement or SHP1-inhibited DCs/DC-EVs with DC-enrichment therapies could substantially augment T-cell antitumor immunity and enhance the efficacy of cancer immunotherapies.Significance:The impacts of nutritional supplements on responses to immunotherapies remain unexplored. Our study revealed that dietary vitamin E binds to and inhibits DC checkpoint SHP1 to increase antigen presentation, prime antitumor T-cell immunity, and enhance immunotherapy efficacy. VitE-treated or SHP1-silenced DCs/DC-EVs could be developed as potent immunotherapies.This article is highlighted in the In This Issue feature, p. 1599
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1
Despite the popular use of dietary supplements during conventional cancer treatments, their impacts on the efficacies of prevalent immunotherapies, including immune-checkpoint therapy (ICT), are unknown. Surprisingly, our analyses of electronic health records revealed that ICT-treated patients with cancer who took vitamin E (VitE) had significantly improved survival. In mouse models, VitE increased ICT antitumor efficacy, which depended on dendritic cells (DC). VitE entered DCs via the SCARB1 receptor and restored tumor-associated DC functionality by directly binding to and inhibiting protein tyrosine phosphatase SHP1, a DC-intrinsic checkpoint. SHP1 inhibition, genetically or by VitE treatment, enhanced tumor antigen cross-presentation by DCs and DC-derived extracellular vesicles (DC-EV), triggering systemic antigen-specific T-cell antitumor immunity. Combining VitE with DC-recruiting cancer vaccines or immunogenic chemotherapies greatly boosted ICT efficacy in animals. Therefore, combining VitE supplement or SHP1-inhibited DCs/DC-EVs with DC-enrichment therapies could substantially augment T-cell antitumor immunity and enhance the efficacy of cancer immunotherapies.Significance:The impacts of nutritional supplements on responses to immunotherapies remain unexplored. Our study revealed that dietary vitamin E binds to and inhibits DC checkpoint SHP1 to increase antigen presentation, prime antitumor T-cell immunity, and enhance immunotherapy efficacy. VitE-treated or SHP1-silenced DCs/DC-EVs could be developed as potent immunotherapies.This article is highlighted in the In This Issue feature, p. 1599
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1
Despite the popular use of dietary supplements during conventional cancer treatments, their impacts on the efficacies of prevalent immunotherapies, including immune-checkpoint therapy (ICT), are unknown. Surprisingly, our analyses of electronic health records revealed that ICT-treated patients with cancer who took vitamin E (VitE) had significantly improved survival. In mouse models, VitE increased ICT antitumor efficacy, which depended on dendritic cells (DC). VitE entered DCs via the SCARB1 receptor and restored tumor-associated DC functionality by directly binding to and inhibiting protein tyrosine phosphatase SHP1, a DC-intrinsic checkpoint. SHP1 inhibition, genetically or by VitE treatment, enhanced tumor antigen cross-presentation by DCs and DC-derived extracellular vesicles (DC-EV), triggering systemic antigen-specific T-cell antitumor immunity. Combining VitE with DC-recruiting cancer vaccines or immunogenic chemotherapies greatly boosted ICT efficacy in animals. Therefore, combining VitE supplement or SHP1-inhibited DCs/DC-EVs with DC-enrichment therapies could substantially augment T-cell antitumor immunity and enhance the efficacy of cancer immunotherapies.Significance:The impacts of nutritional supplements on responses to immunotherapies remain unexplored. Our study revealed that dietary vitamin E binds to and inhibits DC checkpoint SHP1 to increase antigen presentation, prime antitumor T-cell immunity, and enhance immunotherapy efficacy. VitE-treated or SHP1-silenced DCs/DC-EVs could be developed as potent immunotherapies.This article is highlighted in the In This Issue feature, p. 1599